Storia in 2 fonti

Novo Nordisk’s Market Value Sheds $30 Billion—Here’s Why Shares Are Down

Analysts were critical of the Ozempic maker’s failed trial for a new experimental drug.

Raccontata da

forbes.com

cnbc.com

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

forbes.comStai leggendo2 g fa

Novo Nordisk’s Market Value Sheds $30 Billion—Here’s Why Shares Are Down

Analysts were critical of the Ozempic maker’s failed trial for a new experimental drug.

originale

cnbc.com1 g fa

Novo Nordisk shares dive 9% after heart medicine fails trial

The experimental medicine ziltivekimab didn't translate into a statistically meaningful reduction in major cardiovascular adverse events, Novo said Friday.

Leggi questa versione → originale

Timeline cronologica

venerdì 31 luglio 2026·forbes.com
Novo Nordisk’s Market Value Sheds $30 Billion—Here’s Why Shares Are Down
Analysts were critical of the Ozempic maker’s failed trial for a new experimental drug.
venerdì 31 luglio 2026·cnbc.com
Novo Nordisk shares dive 9% after heart medicine fails trial
The experimental medicine ziltivekimab didn't translate into a statistically meaningful reduction in major cardiovascular adverse events, Novo said Friday.